- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship...
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to...
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
FORT MILL, S.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device...
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV;...
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7%...
Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering...
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development...
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025...
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated...
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International ConferenceAddition of TUS to...
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously...
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative...
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage...
HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape...
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE...